Infections in children with down syndrome and acute myeloid leukemia: A report from the Canadian infections in AML research group

Infectious Agents and Cancer

Volumn 8, Issue 1, 2013, Pages

  Tran, Thai Hoa ^a   Mitchell, David ^b   Dix, David ^c   Cellot, Sonia ^d   Ethier, Marie Chantal ^a   Gillmeister, Biljana ^a   Hitzler, Johann ^a   Lewis, Victor ^e   Yanofsky, Rochelle ^f   Johnston, Donna L ^g   Portwine, Carol ^h   Price, Victoria ⁱ   Zelcer, Shayna ^j   Silva, Mariana ^k   Michon, Bruno ^l   Bowes, Lynette ^m   Stobart, Kent ⁿ   Brossard, Josee ^o   Beyene, Joseph ^a,p   Sung, Lillian ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

^c BC CHILDREN S HOSPITAL   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

^e ALBERTA CHILDREN'S HOSPITAL   (Canada)

^f Cancer Care Manitoba ^*  (Canada)

^g CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^h MCMASTER CHILDREN S HOSPITAL   (Canada)

ⁱ IWK HEALTH CENTRE   (Canada)

^j LONDON HEALTH SCIENCES CENTRE   (Canada)

^k Cancer Centre of Southeastern Ontario   (Canada)

^l LAVAL UNIVERSITY   (Canada)

^m New Janeway Childrens Health and Rehabilitation Centre   (Canada)

ⁿ UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^o CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^p MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

Acute myeloid leukemia; Chemotherapy; Children; Down syndrome; Infection

Indexed keywords

CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BACTEREMIA; CHEMOTHERAPY; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; DEATH; DOWN SYNDROME; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; INFECTION; LEUKEMIA RELAPSE; LOW DRUG DOSE; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SEPSIS;

EID: 84888588169     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-8-47     Document Type: Article

References (29)

1. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Hasle H, Clemmensen IH, Mikkelsen M, Lancet 2000 355 9199 165 169 10.1016/S0140-6736(99)05264-2 10675114 (Pubitemid 30068214)
2. Down syndrome and leukemia: new insights into the epidemiology, pathogenesis, and treatment. Ravindranath Y, Pediatr Blood Cancer 2005 44 1 1 7 10.1002/pbc.20242 15486953 (Pubitemid 39602558)
3. Down syndrome and acute lymphoblastic leukaemia. Whitlock JA, Br J Haematol 2006 135 5 595 602 10.1111/j.1365-2141.2006.06337.x 17054672 (Pubitemid 44674071)
4. What's up with down syndrome and leukemia-A lot! Taub JW, Ravindranath Y, Pediatr Blood Cancer 2011 57 1 1 3 10.1002/pbc.23033 21480471
5. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: children's cancer group studies 2861 and 2891. Lange BJ, Kobrinsky N, Barnard DR, Arthur DC, Buckley JD, Howells WB, Gold S, Sanders J, Neudorf S, Smith FO, Woods WG, Blood 1998 91 2 608 615 9427716 (Pubitemid 28053385)
6. Origins of leukaemia in children with Down syndrome. Hitzler JK, Zipursky A, Nat Rev Cancer 2005 5 1 11 20 10.1038/nrc1525 15630411 (Pubitemid 40052321)
7. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Taub JW, Huang X, Matherly LH, Stout ML, Buck SA, Massey GV, Becton DL, Chang MN, Weinstein HJ, Ravindranath Y, Blood 1999 94 4 1393 1400 10438727 (Pubitemid 29380420)
8. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Janka-Schaub GE, van Zantwijk CH, Huismans DR, de Vries E, Rots MG, Peters GJ, Jansen G, Creutzig U, Veerman AJ, Blood 2002 99 1 245 251 10.1182/blood.V99.1.245 11756178 (Pubitemid 34532990)
9. Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Arico M, Ziino O, Valsecchi MG, Cazzaniga G, Baronci C, Messina C, Pession A, Santoro N, Basso G, Conter V, Oncology H, Italian Association of Pediatric, Cancer 2008 113 3 515 521 10.1002/cncr.23587 18521927
10. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Bassal M, La MK, Whitlock JA, Sather HN, Heerema NA, Gaynon PS, Stork LC, Pediatr Blood Cancer 2005 44 1 21 28 10.1002/pbc.20193 15368546 (Pubitemid 39602561)
11. Acute lymphoblastic leukaemia in children with Down syndrome: an updated review. Maloney KW, Br J Haematol 2011 155 4 420 425 10.1111/j.1365-2141.2011. 08846.x 21933171
12. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M, Heerema NA, Bhatia S, Blood 2005 106 13 4043 4049 10.1182/blood-2003-10-3446 16109782 (Pubitemid 41775907)
13. Association between corticosteroids and infection, sepsis, and infectious death in pediatric acute myeloid leukemia (AML): results from the Canadian infections in AML research group. Dix D, Cellot S, Price V, Gillmeister B, Ethier MC, Johnston DL, Lewis V, Michon B, Mitchell D, Stobart K, Yanofsky R, Portwine C, Silva M, Bowes L, Zelcer S, Brossard J, Traubici J, Allen U, Beyene J, Sung L, Clin Infect Dis 2012 55 12 1608 1614 10.1093/cid/cis774 22955431
14. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. Santolaya ME, Alvarez AM, Becker A, Cofre J, Enriquez N, O'Ryan M, Paya E, Pilorget J, Salgado C, Tordecilla J, Varas M, Villarroel M, Viviani T, Zubieta M, J Clin Oncol 2001 19 14 3415 3421 11454890 (Pubitemid 32642195)
15. A prospective search for ocular lesions in hospitalized patients with significant bacteremia. Bouza E, Cobo-Soriano R, Rodriguez-Creixems M, Munoz P, Suarez-Leoz M, Cortes C, Clin Infect Dis 2000 30 2 306 312 10.1086/313648 10671333 (Pubitemid 30131538)
16. Low serum procalcitonin level accurately predicts the absence of bacteremia in adult patients with acute fever. Chirouze C, Schuhmacher H, Rabaud C, Gil H, Khayat N, Estavoyer JM, May T, Hoen B, Clin Infect Dis 2002 35 2 156 161 10.1086/341023 12087521 (Pubitemid 34753900)
17. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric S, Pediatr Crit Care Med 2005 6 1 2 8 10.1097/01.PCC.0000149131.72248.E6 15636651 (Pubitemid 40956461)
18. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, International Sepsis Definitions C, Intensive Care Med 2003 29 4 530 538 10.1007/s00134-003-1662-x 12664219 (Pubitemid 36523666)
19. CDC definitions for nosocomial infections, 1988. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM, Am J Infect Control 1988 16 3 128 140 10.1016/0196-6553(88)90053-3 2841893
20. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J, Blood 2007 110 10 3532 3539 10.1182/blood-2007-05-091942 17660380 (Pubitemid 350159617)
21. Severe toxicities during pediatric acute myeloid leukemia chemotherapy: a report from the Children's Oncology Group. Sung L, Alonzo TA, Gerbing RB, Meshinchi S, Burden L, Raimondi S, Hirsch B, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Wallas T, Smith FO, Gamis A, Am Soc Hematol, Orlando, Florida 2010 116 1071
22. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR, Gold S, Smith FO, Children's Cancer Group S, J Clin Oncol 2003 21 18 3415 3422 10.1200/JCO.2003.08.060 12885836 (Pubitemid 46594074)
23. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M, Chauvenet A, Alvarado CS, Dubowy R, Ritchey AK, Land V, Steuber CP, Weinstein H, Blood 1992 80 9 2210 2214 1384797
24. High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia. Kern W, Kurrle E, Vanek E, Klin Wochenschr 1987 65 16 773 780 10.1007/BF01743253 3477669 (Pubitemid 17121934)
25. Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. Syrjala H, Ohtonen P, Kinnunen U, Raty R, Elonen E, Nousiainen T, Jantunen E, Remes K, Itala-Remes M, Silvennoinen R, Koistinen P, Finnish Leukemia G, Eur J Clin Microbiol Infect Dis 2010 29 10 1211 1218 10.1007/s10096-010-0984-1 20556469
26. Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study. Taga T, Shimomura Y, Horikoshi Y, Ogawa A, Itoh M, Okada M, Ueyama J, Higa T, Watanabe A, Kanegane H, Iwai A, Saiwakawa Y, Kogawa K, Yamanaka J, Tsurusawa M, Pediatr Blood Cancer 2011 57 1 36 40 10.1002/pbc.22943 21557456
27. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature. Abildgaard L, Ellebaek E, Gustafsson G, Abrahamsson J, Hovi L, Jonmundsson G, Zeller B, Hasle H, Ann Hematol 2006 85 5 275 280 10.1007/s00277-005-0045-5 16518605 (Pubitemid 43732648)
28. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M, Leukemia 2005 19 8 1355 1360 10.1038/sj.leu.2403814 15920490 (Pubitemid 41136328)
29. Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome. Al-Ahmari A, Shah N, Sung L, Zipursky A, Hitzler J, Br J Haematol 2006 133 6 646 648 10.1111/j.1365-2141.2006.06097.x 16704441 (Pubitemid 43742781)